DK1354879T3 - Dihydronaphtalenderivatforbindelser og medikamenter indeholdende disse forbindelser som aktiv bestanddel - Google Patents
Dihydronaphtalenderivatforbindelser og medikamenter indeholdende disse forbindelser som aktiv bestanddelInfo
- Publication number
- DK1354879T3 DK1354879T3 DK01994985T DK01994985T DK1354879T3 DK 1354879 T3 DK1354879 T3 DK 1354879T3 DK 01994985 T DK01994985 T DK 01994985T DK 01994985 T DK01994985 T DK 01994985T DK 1354879 T3 DK1354879 T3 DK 1354879T3
- Authority
- DK
- Denmark
- Prior art keywords
- agent
- compounds
- compound
- formula
- active ingredient
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- -1 Dihydronaphthalene derivative compounds Chemical class 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 235000020830 overeating Nutrition 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000392723 | 2000-12-25 | ||
| PCT/JP2001/011255 WO2002051820A1 (en) | 2000-12-25 | 2001-12-21 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1354879T3 true DK1354879T3 (da) | 2007-12-17 |
Family
ID=18858667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01994985T DK1354879T3 (da) | 2000-12-25 | 2001-12-21 | Dihydronaphtalenderivatforbindelser og medikamenter indeholdende disse forbindelser som aktiv bestanddel |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7220864B2 (cs) |
| EP (2) | EP1354879B1 (cs) |
| JP (1) | JP3491635B2 (cs) |
| KR (2) | KR100718906B1 (cs) |
| CN (1) | CN100357280C (cs) |
| AT (1) | ATE370130T1 (cs) |
| BR (1) | BR0116526A (cs) |
| CA (1) | CA2432211C (cs) |
| CZ (1) | CZ20031772A3 (cs) |
| DE (1) | DE60130031T2 (cs) |
| DK (1) | DK1354879T3 (cs) |
| ES (1) | ES2291378T3 (cs) |
| HU (1) | HUP0303636A3 (cs) |
| IL (2) | IL156505A0 (cs) |
| MX (1) | MXPA03005763A (cs) |
| NO (1) | NO327132B1 (cs) |
| NZ (1) | NZ526687A (cs) |
| PL (1) | PL207798B1 (cs) |
| PT (1) | PT1354879E (cs) |
| RU (1) | RU2268262C2 (cs) |
| TW (1) | TWI235748B (cs) |
| WO (1) | WO2002051820A1 (cs) |
| ZA (1) | ZA200304913B (cs) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2004011446A1 (en) * | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
| JP2005104951A (ja) * | 2003-01-17 | 2005-04-21 | Kirin Brewery Co Ltd | 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品 |
| DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308354A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
| DE10308351A1 (de) * | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308353A1 (de) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| JPWO2005103017A1 (ja) * | 2004-04-20 | 2008-03-13 | 小野薬品工業株式会社 | 難溶性薬物の比表面積増大方法 |
| CA2626443A1 (en) * | 2005-11-07 | 2007-05-18 | Irm Llc | Oxazole and thiazole ppar modulators |
| US8741259B2 (en) * | 2008-10-20 | 2014-06-03 | Marvin C. Gershengorn | Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists |
| EP2563777A4 (en) | 2010-04-08 | 2013-09-04 | Us Health | INVERSE AGONISTS AND NEUTRAL AGONISTS FOR THE TSH RECEPTOR |
| WO2012027482A2 (en) * | 2010-08-24 | 2012-03-01 | Georgetown University | Compounds, compositions and methods related to ppar antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4317320A1 (de) * | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| WO1999011255A1 (en) * | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
-
2001
- 2001-12-21 NZ NZ526687A patent/NZ526687A/en not_active IP Right Cessation
- 2001-12-21 DE DE60130031T patent/DE60130031T2/de not_active Expired - Lifetime
- 2001-12-21 DK DK01994985T patent/DK1354879T3/da active
- 2001-12-21 RU RU2003118718/04A patent/RU2268262C2/ru not_active IP Right Cessation
- 2001-12-21 BR BR0116526-7A patent/BR0116526A/pt not_active IP Right Cessation
- 2001-12-21 AT AT01994985T patent/ATE370130T1/de active
- 2001-12-21 CZ CZ20031772A patent/CZ20031772A3/cs unknown
- 2001-12-21 WO PCT/JP2001/011255 patent/WO2002051820A1/ja not_active Ceased
- 2001-12-21 KR KR1020067012331A patent/KR100718906B1/ko not_active Expired - Fee Related
- 2001-12-21 PL PL363583A patent/PL207798B1/pl not_active IP Right Cessation
- 2001-12-21 IL IL15650501A patent/IL156505A0/xx unknown
- 2001-12-21 HU HU0303636A patent/HUP0303636A3/hu unknown
- 2001-12-21 EP EP01994985A patent/EP1354879B1/en not_active Expired - Lifetime
- 2001-12-21 KR KR1020037008566A patent/KR100635315B1/ko not_active Expired - Fee Related
- 2001-12-21 PT PT01994985T patent/PT1354879E/pt unknown
- 2001-12-21 MX MXPA03005763A patent/MXPA03005763A/es active IP Right Grant
- 2001-12-21 CN CNB018226787A patent/CN100357280C/zh not_active Expired - Fee Related
- 2001-12-21 US US10/451,679 patent/US7220864B2/en not_active Expired - Fee Related
- 2001-12-21 JP JP2002552915A patent/JP3491635B2/ja not_active Expired - Fee Related
- 2001-12-21 ES ES01994985T patent/ES2291378T3/es not_active Expired - Lifetime
- 2001-12-21 EP EP06119088A patent/EP1726586A1/en not_active Withdrawn
- 2001-12-21 CA CA2432211A patent/CA2432211C/en not_active Expired - Fee Related
- 2001-12-24 TW TW090132011A patent/TWI235748B/zh not_active IP Right Cessation
-
2003
- 2003-06-18 IL IL156505A patent/IL156505A/en not_active IP Right Cessation
- 2003-06-23 NO NO20032895A patent/NO327132B1/no not_active IP Right Cessation
- 2003-06-24 ZA ZA200304913A patent/ZA200304913B/en unknown
-
2006
- 2006-08-17 US US11/505,359 patent/US20060287304A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1067109A4 (en) | CARBOXYLIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT | |
| NO20032895D0 (no) | Dihydronaftalenderivat-forbindelser og legemidler innholdende disse forbindelsene som den aktive bestanddel | |
| WO2001096311A3 (en) | Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases | |
| EP1122255A4 (en) | CARBONIC ACID DERIVATIVES AND MEDICINES THAT CONTAIN THEM AS ACTIVE INGREDIENTS | |
| NO20072542L (no) | Pyrimidinderivat kondensert med ikke-aromatisk ring | |
| IL156167A (en) | Compounds of ABCA-1 for use in the preparation of a pharmacological preparation for the treatment of diseases following arterio-sclerosis | |
| MY142551A (en) | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | |
| ATE264337T1 (de) | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung | |
| BR0016064A (pt) | Compostos heterocìclicos e seus sais e uso medicinal dos mesmos | |
| EP1108713A4 (en) | CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE COMPONENT | |
| RU2006102129A (ru) | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов | |
| NO20025659D0 (no) | Heterocykliske forbindelser | |
| WO2008043024A3 (en) | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease | |
| EP1602642A4 (en) | IMINO ETHER-DERIVED COMPOUNDS AND MEDICAMENTS COMPRISING SAID COMPOUNDS AS ACTIVE INGREDIENT | |
| NO940274D0 (no) | 2-(4-(-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler | |
| WO2003042194A1 (en) | Carboxylic acid derivative compounds and drugs containing the same as the active ingredient | |
| Klug et al. | New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors | |
| CA2365085A1 (en) | Therapeutic agents for diabetes | |
| Peters et al. | Efficacy and safety of fluvastatin in women with primary hypercholesterolemia | |
| PROFILE | JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381 | |
| Lavery | 5 Questions—and Answers—About Off-Loading | |
| ES2173049A2 (es) | Monoestrer de acido graso y estrogeno como agente antidiabetico e hipolipemiante. | |
| Shaban et al. | Mo-P5: 328 Comparison of effective factors on sleeping from aspect of nurse and hospitalized patient in coronary care unit of hospitals of Tehran University of medical sciences | |
| Bachorik | Therapy and clinical trials | |
| Gajdos et al. | Mo-P5: 329 Rosuvastatin, the alternative of insufficiently effective statins |